✦ LIBER ✦

Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98

✍ Scribed by Loi, S.; Sirtaine, N.; Piette, F.; Salgado, R.; Viale, G.; Van Eenoo, F.; Rouas, G.; Francis, P.; Crown, J. P. A.; Hitre, E.; de Azambuja, E.; Quinaux, E.; Di Leo, A.; Michiels, S.; Piccart, M. J.; Sotiriou, C.

Book ID: 121389731
Publisher: American Society of Clinical Oncology
Year: 2013
Tongue: English
Weight: 313 KB
Volume: 31
Category: Article
ISSN: 0732-183X
DOI: 10.1200/JCO.2011.41.0902

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Prognostic and predictive value ofTP53mu

Prognostic and predictive value ofTP53mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial

✍ Lynnette Fernández-Cuesta, Catherine Oakman, Priscila Falagan-Lotsch, Ke-seay Sm 📂 Article 📅 2012 🏛 BioMed Central 🌐 English ⚖ 307 KB

762 Prognostic and Predictive Value of T

762 Prognostic and Predictive Value of TP53 Mutations in Node-positive Breast Cancer Patients Treated with Anthracycline-or Anthracycline/taxane Based Adjuvant Therapy – Results From the BIG 02-98 Phase III Trial

✍ M. Olivier; L. Fernández-Cuesta; C. Oakman; E. Quinaux; M.S. Dolci; P.A. Francis 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 71 KB

The effect of body mass index on overall

The effect of body mass index on overall and disease-free survival in node-positive breast cancer patients treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial

✍ Evandro de Azambuja; Worta McCaskill-Stevens; Prudence Francis; Emmanuel Quinaux 📂 Article 📅 2009 🏛 Springer US 🌐 English ⚖ 307 KB

The effect of body mass index (BMI) on d

The effect of body mass index (BMI) on disease-free and overall survival in node-positive breast cancer treated with docetaxel and doxorubicin-containing adjuvant chemotherapy: the experience of the BIG 02-98 trial

✍ E. De Azambuja; W. McCaskill-Stevens; E. Quinaux; M. Buyse; J. Crown; P. Francis 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 66 KB

Phase 2 trial of primary systemic therap

Phase 2 trial of primary systemic therapy with doxorubicin and docetaxel followed by surgery, radiotherapy, and adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil based on clinical and pathologic response in patients with stage IIB to III breast cancer : Long-term results from The University of Texas M. D. Anderson Cancer Center Study ID97-099

✍ Ricardo H. Alvarez; Daniel J. Booser; Massimo Cristofanilli; Aysegul A. Sahin; E 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 199 KB 👁 2 views